

ABOVE & BEYOND TRADITIONAL EXPECTATIONS
A HYBRID VENTURES / CAPITAL TEAM

THE MISSION
We partner with seasoned founders of cutting edge fast growth companies needing to raise more capital as they are ready to ignite. Our mission is to add an expertise for developing key American businesses in innovative 1 B+ markets, post-seed and evolved startups poised to succeed beyond expectations!

A HYBRID PLATFORM
We have developed a unique go to market collaboration model. We help set it up with preparation and the proper funding ASK. Let us help you get results. We take on your company and challenges
as long term advisors and partners. We are very selective in the types of investors, founders, team, products and high growth verticals we research to work with. Share your vision with us
PROJECTS
Q - 3 / 2025
AGI / Agriculture-tech / Bio-medical / Energy / Health-lifestyle / Luxe / RE & Development / Technology
APOTHEKA 2.5M
A SaaS platform integrates with Electronic Medical Records Systems in to secure Blockchain eco systems; 2 Patents. Data also used to monitors sports athletes
*lead investor 500K
LUMOPTIK 2M
Reflex-o-meter Assisted Medical equipment for performing epidural and other orthopedic surgical procedures requiring precision
*lead investor over 1M raised
BRIDGE RX 5M
Non opiod/ non addictive medical
Pharma delivery system designed to combat the current opiod crisis.
SITE SEE 10M
AI for communications industry with global reach with international LOI's
connects info on and repairs cell towers especially in
KINETA 30M
Bio technology company with a mission to develop next generation Immunotherapies in cancer. Gone public and looking for volume
GLYTHERIX 20M
Developers of Miltuximab- binds to unique cancer protein marker Glypicam-1(“GPC-1”), enabling a cytotoxic payload delivery direct to tumor, destroys only the cancer cell
MINOMIC 20M
Australian medical cancer research company;
JANGO BIO 20M
Anti-ageing R & D for next generations standards of longevity by replacing natural hormones
MUSSEL POLYMER 25M
Mollusk type superglue reconfigured as C chain.
Dentistry use, contracts with NAVY other US DOD
PECAN TV 40 M
Share new film or video to almost instant animation;
comedy / drama / reality promoting upcoming underrepresented artists
VERSEON 300 M
AI generated data and research producing new medicnes for Cancer Heart and Diabetes. A bio pharma health - life platform focuses on anti ageing, a preventative lifestyle and new research for the newest drugs entering the pharma markets in 2026
Real Estate / executive summaries available for accredited investors only
R E CAL 50M+
Residential -Units
Luxe apartments central location development deals. Partnership with private equity fund, tax incentives
Commercial construction.SANTA YNEZ 8M
Development project; old 50 acre winery, 50 K sq ft partially completed multi-story French chateau style building converts into wellness center, or luxe alz retreat. Airplane landing strip, on site wells, power
IRON ORE and GOLD
Existing MINES
West Australia. Mexico
In Production= international sales / expansion capital neede Information available request to qualified parties bank letter of introduction.
coming Q- 4 2025
* AI generated medical research and wellness platform
* AI key knowledge platform
* Seafood global fishing coop / re-farming
* modular home factories
* ESG tailings / mine cleanup
* Medical supply chain
Connect With Us
Accredited Investors and Entrepreneurs
TEAM :
R Victoria Jodis / Charles Finkelstein / Mark Dirkse / Michael Hunter / Mike Mitchell
Board: Les Goodwin/ Robert Moore Esq. TV: Walt Lusk Public Affairs: Jill Shestokas
Affiliates :
LA Chicago DC Denver Newport Beach Silicon Valley Seattle NYC
Steel Wolf - a boutique consulting company that finds, markets, researches,
sources, collaborates with and invests in new cutting-edge 1B+ business
STEEL WOLF VENTURES
489 South Robertson Bl
Beverly Hills, California 90211Newport Chicago DC Denver Beverly Hills
Miami Silicon ValleyBH 310 855 2282Media
STEEL WOLF VENTURES
Press
STEEL WOLF VENTURES PIERCING BILLION DOLLAR MARKETS
BEVERLY HILLS, CA – November 28, 2021
Steel Wolf Ventures (SWV) today announced more than $250M in active projects with a market potential of 1B+ each. This record-breaking year for growth equity, has buoyed SWV's entrepreneurs, young high-growth companies, ESG, AI and SaaS, as well as breakthrough health and medical businesses to secure immediate as well as on-going funding.
Business leader and SWV founder, R. Victoria Jodis said her elite boutique venture firm accelerates their clients’ access to the right money for post seed/pre-IPO businesses and inventors. “We keenly focus on our client’s long-term development and excel in delivering world class results.
“Our team includes stellar investment bankers, board members including Les Goodman / Beverly Hills, corporate attorney Robert Moore, Principal Mark Dirkse and our affiliates. Each has distinguished records- from consummating billion dollar deals globally to negotiating through both entrepreneurial and corporate stages.
"We leverage our experience, abilities, and relationships as strategic partners developing and accelerating early-stage businesses. Founders can focus on their cutting-edge products and growing revenue,” she said.
SWV’s revolutionary projects are in ag-tech, biotech, Medtech, SaaS, AI, comms, health and wellness, lifestyle, manufacturing, and real estate development. Appreciating culture, SWV unpacks prosperity with social integrity and NetZero mandates. “Investors in this ecosystem can prosper and exponentially create American jobs with a fiscally and an economically responsible and pro-business approach while supporting both pro-environment choices and promoting human rights,” Jodis concluded.
CONTACT:
victoria@steelwolfventures.com
XXX
STEEL WOLF VENTURES REDEFINES TRADITIONAL CAPITAL RAISES
Seasoned Investor Group Niche Building
Beverly Hills, CA, July 22, 2019 - Newly formed Steel Wolf Ventures (SWV) has announced a hybrid business investment and equity funding model for cutting edge entities beyond family and friends financing in capitalization needs but yet not large enough for traditional institutional funding.
Recognizing a void in fundraising options for emerging companies, SWV partners strategically researches innovative ventures in potential $1B+ plus markets, poised to thrive with the right investment or financing Their choice is to foster and raise impact investments in five sectors - bio, tech, health & medical (including CBD/cannabis), clean energy and RE/development.
Partner and Founder, R. Victoria Jodis, a California entrepreneur, has significant inside experience with business and media. Jodis said, “the partners found worthy companies that consistently fell into a ‘financial black hole.’ Investment Bankers are beyond their reach and small/ineffective crowdfunding sites either can’t deliver enough money or are not fast enough.”
“Emerging and startup companies needing $5 million and up to $50- 500 million in capital are quite different than large established corporations with EBITDA seeking capital, development or M&A financing. They can’t grow their businesses without private equity and other investment opportunities” Jodis continued. “Entrepreneurs have varying degrees of business savvy. To be without a clear development timetable, market strategy, product integrity, a detailed budget and plan to profitability or a potential exit strategy is business suicide. Over all though, they all have the very same single issue – money,” Jodis concluded.
Fellow affiliates and partners say “Steel Wolf provides an effective and efficient way for small emerging firms to compete for capital needed to make their companies viable entities.”
As a team - we can help scale- and are stronger.
Steel Wolf’s hybrid business model discards Investment Bank/Wall Street structure. Modest upfront fees include expenses, team evaluation and strategic development. SWV takes some ownership, provides engagement with the client-founder as new board members and partners while marketing and developing accredited investor streams or other private equity sources, and potential new channels so the founder fully focuses on product, markets and revenue.
SWV raises for Q3 2019 include these companies with double digit, high growth and sustainable $1B+ market potential:
Accredited Investors / Entities / Entrepreneurs
###
For more Information: victoria@SteelWolfVentures.com
April 2023
For investors who want to act rather than stand still, execution of acquisitions and sales has been hampered by market volatility and illiquidity. Many deals have been extended or canceled altogether due to the inability to wrap up previously approved financing. The banks are overwhelmed, making traditional financing hard to execute despite low-interest rates.
During this virus crisis, some businesses may need an investor lifeline while a small percentage- are doing very well right now and growing faster than they can keep up with. In either case, an investor connection is a must-have tool to accelerate outreach. Here are many of the opportunities Family Office Investors are currently seeking:
- Distressed Opportunities: Assets & companies which had good profits and revenue before the virus crisis but now need a cash infusion or investment to make it through this period.
- Growth Opportunities: Healthcare, medical supply, medical equipment, decontamination services, supply chain services, or subscription/recurring revenue services related to these areas.
- Subscription Offerings: Recurring revenue and subscription service companies that have not been damaged by the virus.
OCTOBER 2025
Newsmakers
MAVERICKS & MONEY
Billionaire New Zealand Brothers’ Plans to Rebuild Malibu’s Coastline Revealed
After Snapping Up $65 Million in Wildfire-Damaged Plots
By Joy Dumandan September 1, 2025
MALIBU REDEVELOPMENT TRENDS
Malibu Investor Revealed as He Gives Glimpse Into Rebuilding Plans - https://www.youtube.com/watch?v=0gVc5wCUwmM
NZINC/YouTube, Jeff Gritchen/MediaNews Group/Orange County Register via Getty Images
The foreign investor secretly scooping up $65 million worth of wildfire-damaged lots along Malibu's coastline has been confirmed as the billionaire Mowbray brothers from New Zealand, Realtor.com® can reveal.
Zuru, a toy, consumer goods, and tech/construction company was founded by brothers Nick and Mat Mowbray in 2003.
Four additional plots have since been purchased.
Nick and Mat have spent a lot of time in Malibu, according to Marcel Fontijn, director of U.S. operations for Zuru unit Zuru Tech."When the fire happened, it hit home for them. They want to be part of [rebuilding Malibu]," Fontijn tells Realtor.com. "They wanted to be part of the future of it. And it feels close to home; you have more vested in it."
In July 2025, Nick, who was a keynote speaker at the China Business Summit in New Zealand, told the audience
the brothers had "bought a lot of the land in Malibu along where all the fires [happened]."
"I think we've got about 12 sections there right now along the front, and we're actually building our own Zuru Tech buildings to redevelop that whole Malibu beachfront at the moment," he told the audience."That'll be the first projects we do internally before we actually start opening it up to people to use long term."Local media in New Zealand reported that the brothers were pushing ahead with plans to manufacture "cut-price factory-built houses on a global scale."
However, Fontijn tells Realtor.com that Zuru Tech does not plan to produce cut-price factory-built housing on the plots. Rather, some parts will be manufactured overseas.

MARCH 2020
The Case for Private Markets
excerpts - by Jason Frishman
Recent stock market declines in response to the uncertainty arising from the spread of the novel Covid-19 Coronavirus have caused many investors to reassess their portfolios. Stocks have been sold at the fastest rate since the financial crisis of 2007-2008. Investors seeking the relative safety of U.S. Treasury bonds have bid their prices up, driving down yields to historic lows.
In such uncertain times, where risks abound in any investment opportunity, investors should consider allocating capital to invest in the private markets. If you are taking risk investing in public or private equities, you should consider taking the risk which comes with the possibility of an outsized return. Those wild price gyrations of the public markets -- down several points one day, back up another, only to plummet again the next -- really unnerve most investors. And when the declines get as bad as they have recently, many investors throw in the towel and sell, fearful that more pain is ahead.
Publicly traded stocks face a double whammy when a market disruption occurs, such as the Covid-19 outbreak. As forecasters begin to talk about a looming recession, investors anticipate declining earnings, and are no longer willing to pay a lofty multiple for those earnings. When multiples contract, a stock whose earnings decline by X may see its price decline by 2X, or 3X, or even more.
Not so in the private markets. Entrepreneurs looking to raise capital for their private businesses offer investors shares in a portion of the company that reflect its value at that time. Investors are attracted by the opportunity to get in early and hold shares in the hope of a future reward -if the company goes public or gets bought out at a premium. Shares are not traded publicly so they are not subject to the volatility that comes from waves of investor panic and pessimism when broad market conditions deteriorate. It’s the ultimate buy and hold strategy, which many veteran investors say is the best way to build wealth over the long term.
The mainstream media and Wall Street analysts would have investors believe that public stocks are far safer than private stocks. But recessions like Covid-19 and scandals like Enron continue to prove the truth: there is risk everywhere. Some investors choose an asset which offers outsized returns like private market stocks, where one’s money can make a difference in the company being invested in, and create real value in the world.
For many years, opportunities to invest in private companies were restricted to accredited (high net worth) investors and largely controlled by venture capitalists and private equity firms. But this all changed with a new regulation under Section 4(a)(6) (Reg CF) of the JOBS Act, which allows investors of any means to invest in private companies. Under this regulation, private companies offer their securities in various formats - events, online, or pitch panels - which enables these investors to participate
Owning securities that are not publicly traded comes with a small cost – a lack of liquidity. This can be a dual-edged sword. Investors like to know they can have access to their funds, but they can also have a tendency to sell stock at inopportune times during market panics. Nonetheless, personal circumstances can change over time and make illiquidity a problem for an investor. While early stage private companies may be immune from the risk associated with trading volatility, they are a riskier proposition than larger, more established companies. Not all startups will succeed. So as one dives into the world of private investing, it makes sense to keep some basic principles in mind.
Number one: diversify. Investing in multiple offerings decreases your specific risk in any one investment.
Number two: assess your tolerance for risk. Don’t allocate more to higher risk investments than you can afford to lose.
Number three: think long term. Investing in early stage companies creates the opportunity to participate in significant growth, but investors should expect it may take several years or more for such an investment to pay off.
Keeping those principles in mind, there is no reason an investor should not consider private market investing as part of a broadly diversified portfolio.

OCT 8 2025
Scripps Research-led team receives $14.2M NIH award to map the body’s “hidden sixth sense”
Ardem Patapoutian, Li Ye and Xin Jin.credits
An NIH-backed effort aims to decode how the nervous system monitors internal organs.
LA JOLLA, CA—How does your brain know when you need to breathe, when your blood pressure drops or when you’re fighting an infection? The answer lies in interoception: an understudied process by which the nervous system continuously receives and interprets the body’s physiological signals to keep vital functions running smoothly. Now, a collaborative team at Scripps Research and the Allen Institute have received the National Institutes of Health (NIH) Director’s Transformative Research Award to create the first atlas of this internal sensory system.
Nobel Prize-winning neuroscientist Ardem Patapoutian will lead the project with Li Ye, the N. Paul Whittier Chair in Chemistry and Chemical Biology at Scripps Research, and Bosiljka Tasic, the Director of Molecular Genetics at the Allen Institute. As a co-investigator, Scripps Research Associate Professor Xin Jin will lead the genomic and cell type identification part of this NIH-backed initiative. The team will receive $14.2 million in funding over five years.
“My team is honored that the NIH is supporting the kind of collaborative science needed to study such a complex system,” says Patapoutian, the Presidential Endowed Chair in Neurobiology at Scripps Research.
Patapoutian, who shared the 2021 Nobel Prize in Physiology or Medicine for discovering cellular sensors of touch, will use the NIH award with his team to decode interoception.
“We hope our results will help other scientists ask new questions about how internal organs and the nervous system stay in sync,” adds Ye. Like Patapoutian, he’s also a Howard Hughes Medical Institute Investigator.
Established in 2009, the Transformative Research Award supports interdisciplinary projects that cross conventional boundaries and open new directions in science. This accolade is part of the NIH Common Fund’s High-Risk, High-Reward Research program, which promotes ideas aimed at filling major gaps in our understanding of human health—the kind of endeavors that might struggle to gain funding through traditional channels.
Unlike classic senses, such as smell, sight and hearing—which are external and rely on specialized sensory organs—interoception operates through a network of neural pathways that monitor functions like circulation, digestion and immune activity. Because these signals come from deep within the body and are often processed outside conscious awareness, interoception is often described as our “hidden sixth sense.”
Despite its importance, interoception has been historically neglected because of its complexity. Signals from internal organs spread widely, often overlap and are difficult to isolate and measure. Sensory neurons that carry these messages weave through tissues—ranging from the heart and lungs to the stomach and kidneys—without clear anatomical boundaries.
With support from the NIH, the team will chart how sensory neurons connect to a wide range of internal organs, including the heart and gastrointestinal tract. Using their findings, the researchers aim to build a comprehensive atlas that anatomically and molecularly catalogs these neural pathways.
The anatomical part of the project will label sensory neurons and then apply whole-body imaging to follow their paths from the spinal cord into different organs, generating a detailed 3D map of the routes and branching patterns. In the molecular component, the team will use genetic profiling to identify the various cell types of sensory neurons—for example, showing how neurons that send signals from the gut differ from those linked to the bladder or fat. Together, these complementary datasets will produce the first standardized framework for mapping the body’s internal sensory wiring.
By decoding interoception, the team also hopes to uncover core principles of body-brain communication that could guide new approaches to treating disease. Dysregulation of interoceptive pathways has been implicated in conditions ranging from autoimmune disorders and chronic pain to neurodegeneration and high blood pressure.
“Interoception is fundamental to nearly every aspect of health, but it remains a largely unexplored frontier of neuroscience,” says Jin, who’s a Howard Hughes Medical Institute Freeman Hrabowski Scholar. “By creating the first atlas of this system, we aim to lay the foundation for better understanding how the brain keeps the body in balance, how that balance can be disrupted in disease and how we might restore it.”

DUOLINGO - Pittsburgh PA = hot Tech Startup zone
Dec 4 2019

PE / VC Startups at 5 year all time high
November 2019

SANDBOX VR - Hollywood celebrities invest
October 22 2019
Octobe 2025
About Us
Our Mission
We're Hiring!
Resources
Tutorials
Brand Assets
Contact Us
SteelWolfPartners@gmail.com
STEEL WOLF VENTURES © 2020
Steel Wolf, a private company, and through affiliates, partners and the BIZStars TV- VENTURE.Report , accelerates the commercial marketing of Real Estate, Development and other B2B/B2C Business Ventures to an audience inclusive of Angel, VC, Private Equity and accredited investors. Steel Wolf is neither a registered securities dealer or investment adviser. Efforts are made to provide any and all information that is obtained from the entrepreneur about each project and transaction, which may be reasonably included as content for broadcast. We make no warranties or representations as to claims made by the buyer, the seller, or about the asset, lender or product, guarantee any rate of return nor directly provide funding for any transaction. All due diligence in every transaction is and remains the responsibility of the owner, investor, buyer, lender and seller. Communications are considered confidential unless approved by us for broadcast or release.
The information provided herein does not constitute investment advice. Nor does it constitute an offer or invitation to purchase or subscribe for any securities or a solicitation of an offer to sell any securities or any other banking or real estate product or service in the United States or any jurisdiction or in any circumstances in which such an offer, invitation or solicitation is not authorized or is unlawful. Your continued use of this information shall be deemed an acceptance of these limitations.






